Fresh Tracks Therapeutics improves performance as board continues exploring M&A options

BOULDER — Fresh Tracks Therapeutics Inc., the Boulder-based pharmaceutical company formerly called Brickell Biotech, saw year-over-year improvement in its bottom and top lines in the fourth quarter of 2022 and for the full 2022 fiscal year.

The improved performance comes during a pivotal time for FTT, which is in the process of examining its options for a merger or sale.

Fresh Tracks posted a net loss of $4.5 million on sales of $2.1 million for the fourth quarter of 2022 compared to a net loss of $6.1 million on $100,000 in sales for the same period in 2021.

For…